Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Starbucks reported for 9 months of fiscal year 2023

8/2/23 SBUX

Electronic Arts reported for 3 months of fiscal year 2024

8/2/23 EA

Lumen reported for 6 months of 2023

8/2/23 LUMN

SberMegaMarket removed the reference to the bank from its name

8/1/23 SBER

SFI reported for 6 months of 2023 by RAS

8/1/23 SFIN

European Electrotechnics reported for 6 months of 2023 by RAS

8/1/23 EELT

UCS reported for 6 months of 2023 by RAS

8/1/23 UCSS

Aeroflot reported for 6 months of 2023 by RAS

8/1/23 AFLT

Private investors set a record

8/1/23 MOEX

Qiwi sees no significant outflow of customers after regulator restrictions

8/1/23 QIWI